- Home
- ATLCP vs SNN Comparison
ATLCP vs SNN Comparison
Compare ATLCP & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATLCP
- SNN
- Stock Information
- Founded
- ATLCP N/A
- SNN 1856
- Country
- ATLCP United States
- SNN United Kingdom
- Employees
- ATLCP 386
- SNN N/A
- Industry
- ATLCP Finance: Consumer Services
- SNN Industrial Specialties
- Sector
- ATLCP Finance
- SNN Health Care
- Exchange
- ATLCP Nasdaq
- SNN Nasdaq
- Market Cap
- ATLCP N/A
- SNN 12.4B
- IPO Year
- ATLCP N/A
- SNN 1999
- Fundamental
- Price
- ATLCP $22.68
- SNN $29.38
- Analyst Decision
- ATLCP
- SNN Strong Buy
- Analyst Count
- ATLCP 0
- SNN 1
- Target Price
- ATLCP N/A
- SNN N/A
- AVG Volume (30 Days)
- ATLCP N/A
- SNN 683.3K
- Earning Date
- ATLCP N/A
- SNN 08-01-2024
- Dividend Yield
- ATLCP N/A
- SNN 2.55%
- EPS Growth
- ATLCP N/A
- SNN 39.77
- EPS
- ATLCP N/A
- SNN 0.35
- Revenue
- ATLCP N/A
- SNN $5,642,000,000.00
- Revenue This Year
- ATLCP N/A
- SNN $6.92
- Revenue Next Year
- ATLCP N/A
- SNN $5.43
- P/E Ratio
- ATLCP N/A
- SNN $41.81
- Revenue Growth
- ATLCP N/A
- SNN 5.48
- 52 Week Low
- ATLCP N/A
- SNN $21.53
- 52 Week High
- ATLCP N/A
- SNN $31.72
- Technical
- Relative Strength Index (RSI)
- ATLCP 44.82
- SNN 45.92
- Support Level
- ATLCP $22.65
- SNN $28.26
- Resistance Level
- ATLCP $22.97
- SNN $29.64
- Average True Range (ATR)
- ATLCP 0.19
- SNN 0.37
- MACD
- ATLCP 0.00
- SNN 0.02
- Stochastic Oscillator
- ATLCP 28.74
- SNN 48.33
About ATLCP Atlanticus Holdings Corporation 7.625% Series B Cumulative Perpetual Preferred Stock no par value per share
Atlanticus Holdings Corp invests in the financial services industry. It provides various credit and related financial services and products to or associated with the financially underserved consumer credit market. The operating business segments are the Credit as a Service and the Auto Finance segment. It generates maximum revenue from the Credit as a Service segment.
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 41% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.